Table 2.
Univariate and multivariate logistic regression analyses of prognostic factors for recurrence probability in the training cohort
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Variables | OR (95% CI) | P | OR (95% CI) | P |
| Age (≥65 vs. <65) (years) | 2.429 (1.123–5.252) | 0.024 | ||
| ORR (non-ORR vs. ORR) | 2.399 (1.253–4.592) | 0.008 | ||
| Tumor number (multiple vs. solitary) | 1.628 (0.928–2.855) | 0.089 | ||
| Differentiation | 1.74 (1.19–2.545) | 0.004 | 1.696 (1.026–2.803) | 0.039 |
| MVI | ||||
| 1 vs. 0 | 2.828 (1.17–6.839) | 0.021 | 1.452 (1.148–4.704) | 0.034 |
| 2 vs. 0 | 6.364 (0.788–51.374) | 0.082 | 10.309 (1.816–130.179) | 0.017 |
| ALBI grade (grade 2 vs. grade 1) | 2.263 (1.015–5.047) | 0.046 | ||
| ECOG PS | ||||
| Score 1 vs. score 0 | 1.54 (1.261–1.718) | 0.003 | ||
| Score 2 vs. score 0 | 1.851 (0.894–3.833) | 0.097 | ||
| Pre-HAIC AFP (≥400 vs. <400) (ng/ml) | 1.593 (0.902–2.815) | 0.109 | 6.592 (2.524–17.221) | <0.001 |
| Pre-HAIC CA19-9 (>35 vs. ≤35) (U/ml) | 1.582 (0.853–2.935) | 0.146 | ||
| Pre-HAIC NLR (≥5 vs. <5) | 5.429 (1.22–24.163) | 0.026 | 1.815 (1.123–10.248) | 0.025 |
| Pre-HAIC SII (≥609.9 vs. <609.9) | 1.767 (1.006–3.106) | 0.048 | ||
| Preoperative AFP (≥400 vs.<400) (ng/ml) | 2.063 (1.099–3.875) | 0.024 | ||
| Preoperative PIVKA-II (>40 vs. ≤40) (mAU/ml) | 1.333 (0.719–2.473) | 0.015 | ||
| Preoperative CA19-9 (>35 vs. ≤35) (U/ml) | 2.182 (1.138–4.187) | 0.001 | ||
| Preoperative SIRI (≥1.1 vs.<1.1) | 1.748 (0.953–3.205) | 0.071 | 3.142 (1.351–7.306) | 0.008 |
| Preoperative NLR (≥5 vs.<5) | 5.457 (0.678–43.909) | 0.111 | 13.952 (1.185–164.202) | 0.036 |
| Postoperative AFP (>25 vs. ≤25) (ng/ml) | 4.08 (1.929–8.63) | <0.001 | 4.669 (1.398–15.591) | 0.012 |
| Postoperative PIVKA-II (>40 vs. ≤40) (mAU/ml) | 3.144 (1.477–6.695) | 0.003 | ||
| Postoperative CA19-9 (>35 vs. ≤35) (U/l) | 1.877 (0.96–3.669) | 0.066 | ||
AFP, alpha-fetoprotein; ALBI, albumin–bilirubin; CA19-9, carbohydrate antigen 19-9; ECOG PS, Eastern Cooperative Oncology Group performance score; HAIC, hepatic artery infusion chemotherapy; MVI, microvascular invasion; NLR, neutrophil-to-lymphocyte ratio; OR, odds ratio; ORR, objective response rate; PIVKA-II, protein induced by vitamin K absence or antagonist-II; SII, systemic immune-inflammation index; SIRI, systemic inflammatory response index.